GoodRx stock rises 5% after new CEO appointment

GoodRx appoints Wendy Barnes as CEO starting January 1, 2025; shares rise 5%. Analyst predicts her experience will enhance market leadership amid industry uncertainties.

Meta Platforms added to Raymond James Favorites List

GoodRx stock moves on exclusive 30-day offer of weight management drug Qsymia

GoodRx offers Qsymia at $149 for 30-day supply, expanding access to weight-loss medications amid rising obesity rates, despite previous stock fluctuations.